NEW
Cosentyx

Cosentyx

secukinumab

Manufacturer:

Novartis

Distributor:

Zuellig
/
Four Star
Concise Prescribing Info
Contents
Secukinumab
Indications/Uses
Moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. Alone or in combination w/ methotrexate for active psoriatic arthritis in adults when DMARD therapy has been inadequate. Active ankylosing spondylitis in adults w/ inadequate response to conventional therapy. Active non-radiographic axial spondyloarthritis w/ objective signs of inflammation as indicated by elevated C-reactive protein &/or MRI evidence in adults w/ inadequate response to NSAIDs.
Dosage/Direction for Use
SC Plaque psoriasis 300 mg w/ initial dosing at wk 0, 1, 2, 3 & 4, followed by mthly maintenance dosing. Each 300-mg dose is given as 2 SC inj of 150 mg. Psoriatic arthritis Patient w/ concomitant moderate to severe plaque psoriasis or anti-TNFα inadequate responder 300 mg w/ initial dosing at wk 0, 1, 2, 3 & 4, followed by mthly maintenance dosing. Each 300-mg dose is given as 2 SC inj of 150 mg. Other patient 150 mg w/ initial dosing at wk 0, 1, 2, 3 & 4, followed by mthly maintenance dosing, can be increased to 300 mg based on clinical response. Ankylosing spondylitis 150 mg w/ initial dosing at wk 0, 1, 2, 3 & 4, followed by mthly maintenance dosing, can be increased to 300 mg based on clinical response. Each 300-mg dose is given as 2 SC inj of 150 mg. Non-radiographic axial spondyloarthritis 150 mg w/ initial dosing at wk 0, 1, 2, 3 & 4, followed by mthly maintenance dosing.
Contraindications
Hypersensitivity. Clinically important, active infection eg, active TB.
Special Precautions
Discontinue immediately in case of anaphylactic or other serious allergic reactions. Potential to increase risk of infections. Closely monitor patient if a serious infection develops & discontinue treatment until infection resolves. Consider anti-TB therapy prior to initiation in patients w/ latent TB. Reports of new or exacerbations of inflammatory bowel disease (including Crohn's disease & ulcerative colitis). Not recommended in patients w/ inflammatory bowel disease. Concurrent administration w/ live vaccines. Concomitant immunosuppressive therapy eg, biologics, or phototherapy. Patients w/ chronic infection or history of recurrent infection. Latex-sensitive individuals. Patients w/ renal/hepatic impairment. Avoid use during pregnancy. Lactation. Women of childbearing potential should use effective contraception during & for at least 20 wk after treatment. Childn <18 yr.
Adverse Reactions
Upper resp tract infections. Oral herpes, tinea pedis; headache; rhinorrhoea; diarrhoea, nausea; fatigue.
Drug Interactions
Should not be given w/ live vaccines.
ATC Classification
L04AC10 - secukinumab ; Belongs to the class of interleukin inhibitors. Used as immunosuppressants.
Presentation/Packing
Form
Cosentyx soln for inj (pre-filled pen) 150 mg/mL
Packing/Price
(SensoReady pen) 1's
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign up for free
Already a member? Sign in